Drug Trial Radar · NCT06798909
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jul 22, 2025
Primary completion
Nov 30, 2030
Study completion May 31, 2031
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \[both dose adjusted per Food and Drug Administration (FDA) label\] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study. Estimated Time to Complete Enrollment: 4 years
Conditions
- Cytomegalovirus (CMV)
- Kidney Transplant; Complications
- Kidney Diseases
Interventions
Valganciclovir (Pre-emptive CMV Therapy)Drug
Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
Valganciclovir CMV ProphylaxisDrug
Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 200 days post transplantation as prophylaxis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of endpoint committee (EC)-confirmed CMV disease (either syndrome or end-organ) by 1-year post-transplant.Time frame: Within 1-year post-transplant
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco School of Medicine
San Francisco, California · Recruiting
University of Miami Miller School of Medicine
Miami, Florida · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Not yet recruiting
Robert Wood Johnson Health Network Barnabas Health
Livingston, New Jersey · Recruiting
Duke University
Durham, North Carolina · Recruiting
University of Texas Southwestern
Dallas, Texas · Not yet recruiting
Medical College of Virginia Commonwealth
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.